Physician profile
Suhail Dohad
NPI 1730151085
$801,585.55
in general payments reported to CMS, 2019-2025
51 companies · $165K in 2025
The $165K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $57K · 2021: $57K · 2022: $86K · 2023: $129K · 2024: $157K · 2025: $165K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $240K · Consulting Fee: $87K · Travel and Lodging: $71K · Food and Beverage: $44K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,500 · Grant: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $239,575.00 |
| Consulting Fee | $86,798.50 |
| Travel and Lodging | $71,302.10 |
| Food and Beverage | $43,876.46 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,500.00 |
| Grant | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $367,445.14 | 2019-2025 | Indigo System, Ruby Coil, Penumbra System |
| Boston Scientific Corporation | $235,503.56 | 2019-2025 | General - Vascular Access, General - Therapies, Wolverine Coronary Cutting Balloon |
| Abbott Laboratories | $140,630.39 | 2019-2025 | Diamondback Coronary, Xience Skypoint, Optis |
| Shockwave Medical, INC | $13,303.69 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $11,043.00 | 2019-2024 | Xarelto |
| Philips North America LLC | $10,737.31 | 2019-2025 | Coronary Other, (Bq9) Coronary Ivus, (6574) Coronary Other |
| Abiomed | $5,198.88 | 2019-2025 | Impella |
| Edwards Lifesciences Corporation | $3,898.48 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Pascal |
| Recor Medical INC | $3,225.49 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Ge Healthcare | $2,373.05 | 2023-2024 | |
| Medtronic, INC. | $1,397.46 | 2021-2025 | Symplicity G3, Affera Mapping System, Endurant Iis |
| Cardiovascular Systems INC. | $901.21 | 2019-2023 | |
| Teleflex LLC | $843.20 | 2019-2025 | Manta, Guideliner |
| Heartflow, INC. | $457.60 | 2023-2025 | Ffrct |
| Amgen INC. | $454.94 | 2019-2024 | Repatha |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cathworks, INC. | $428.02 | 2019-2025 | Ffrangio |
| Surmodics, INC. | $405.85 | 2022-2025 | Pounce Venous Thrombectomy System, Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy |
| Cook Medical LLC | $319.29 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $316.88 | 2019-2020 | |
| Inari Medical, INC. | $313.43 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Avinger INC. | $235.35 | 2019 | |
| Ablative Solutions, INC. | $223.27 | 2020-2023 | |
| Neovasc Medical INC | $210.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $170.77 | 2019-2025 | |
| Pfizer INC. | $151.48 | 2023-2025 | |
| Asahi Intecc USA, INC. | $146.16 | 2025 | Asahi Coronary Wires |
| Medtronic Vascular, INC. | $144.18 | 2019 | |
| Siemens Medical Solutions USA, INC. | $134.95 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.01 | 2019-2023 | Lifevest |
| Biotronik INC. | $95.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $86.29 | 2019-2025 | Camzyos, Eliquis |
| Cordis US Corp. | $80.87 | 2025 | Selution Slr Ptca |
| Imperative Care, INC | $66.40 | 2024 | Symphony Catheter |
| Astrazeneca Pharmaceuticals Lp | $61.42 | 2024-2025 | Wainua, Farxiga |
| Angiodynamics, INC. | $61.02 | 2024-2025 | Alphavac |
| Reflow Medical INC | $59.95 | 2025 | |
| Scpharmaceuticals INC. | $49.26 | 2023-2025 | |
| Getinge USA Sales, LLC | $46.06 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $44.35 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $33.28 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $28.92 | 2024 | Evkeeza |
| Itamar Medical INC | $24.98 | 2023 | Watchpatone |
| Novo Nordisk INC | $24.93 | 2024 | Ozempic |
| Sanofi-Aventis U.S. LLC | $24.59 | 2019 | |
| Genzyme Corporation | $22.31 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.71 | 2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $20.41 | 2022 | |
| Kestra Medical Technology Services, INC. | $18.43 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,684.44 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suhail Dohad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.